Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA: Key FY 2019 Warning Letter Trend Is Inadequate Testing For API Impurities

Sep 20 2019

• By Joanne S. Eglovitch

Vintage inscription made by old typewriter, warning — agency wants no more genotoxic surprises • Source: Shutterstock

Related Content

FDA Warning Letter Hits Akorn’s Subpar Root Cause Investigations

Jul 10 2019

FDA Warning Letters Hit Three Repackers For Failing To Identify Original API Makers

Jul 03 2019

US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis

Aug 16 2019

US FDA Scrutizes Process Risks After Finding Nitrosamines In ARBs

Aug 29 2019

The Quality Lowdown: No Excuses For Homeopathic, CMO, OTC Quality Failures

Apr 02 2019

FDA Expects Drug GMP Warning Letter Tally To Reach 90 This Year

Sep 28 2018

Data Integrity Guidance Adds Focus On Culture, Best Practices And APIs

Dec 12 2018

US FDA Warning Letter Hits Huahai For Failure To Prevent Valsartan Contamination

Dec 13 2018

Additional Topics

United States Manufacturing Quality Enforcement BioPharmaceutical

More from Manufacturing

More from Compliance

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window